Carticept Medical, Inc., a private, venture capital-backed medical device company, is dedicated to improving the quality of life for patients with osteoarthritis or cartilage damage through the development of novel therapies.
An estimated 27 million Americans suffer from osteoarthritis, a chronic degenerative joint disease characterized by the breakdown of the joint’s cartilage. An additional two million Americans injure the cartilage in their knees each year. Many people do not respond well to current medical treatments or are not eligible for major surgery such as a total joint replacement. Carticept’s mission is to develop and market products to help physicians treat osteoarthritis and cartilage injuries more effectively.